Network identification

PURI

https://redirect.ema.europa.eu/resource/2221162

Network ID

2221162

Network name and Acronym

EU Pharmacoepidemiology and Pharmacovigilance (PE&PV) Research Network

Network countries

Netherlands

ENCePP partner

No
Network description
The European Pharmacoepidemiology and Pharmacovigilance research network (EU PE&PV Research Network) is a public academic partnership led by the Division of Pharmacoepidemiology and Clinical Pharmacology at the Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands. The EU PE&PV Research Network brings together 27 European research centers in 13 countries. Established in 2015, the network has, as of February 2024, successfully completed 12 projects spanning different therapeutic areas. All projects are registered in the EU PAS register.
Network details
Network funding:
Other

Contact

Institutions that are part of this network

Pharmacoepidemiology Group, London School of Hygiene & Tropical Medicine (LSHTM)
Division of Pharmacoepidemiology & Clinical Pharmacology (PECP), Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University
Unit of Clinical Psychopharmacology and Drug Epidemiology, University of Verona
Health Services Research and Pharmacoepidemiology Unit (HSRP Unit) FISABIO
Netherlands Pharmacovigilance Centre Lareb
School of Pharmacy/Kuopio Research Center of Geriatric Care, University of Eastern Finland (Gerho)
Pedianet network
Clinical Pharmacology, Vall d'Hebron Institut de Recerca (VHIR)
University Medical Center Utrecht (UMCU)
Department of Social Pharmacy, Faculty of pharmacy, University of Ljubljana
The PHARMO Institute for Drug Outcomes Research (PHARMO Institute)
Pharmacoepidemiology Research Collaboration (PRC), University of Copenhagen
Porto Pharmacovigilance Centre, Faculty of Medicine, University of Porto (UFPorto)
Servicio Navarro de Salud-Osasunbidea
Centre for Health Protection (RIVM-GZB), National Institute for Public Health & Environment
Department of Medicine/Laboratory of Hygiene and Environmental Protection, Democritus University of Thrace
Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, IDIAPJGol
The Norwegian Institute of Public Health
Agenzia regionale di sanità della Toscana (ARS)
Centre de pharmaco-épidémiologie de l'APHP
The Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO)
Agencia Española de Medicamentos y Productos Sanitarios (Spanish Agency for Medicines and Medical Devices, AEMPS)

Studies conducted by the network

ACCESS template protocol for safety of COVID-19 vaccines
ACCESS template protocols for effectiveness of COVID-19 vaccines (ACCESS-effectiveness)
Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (ACCESS-BGR)
Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU
Cohort Event Monitoring of safety of COVID-19 vaccines (Early-) Covid-Vaccine-Monitor (Covid-Vaccine-Monitor ECVM CVM)
Cohort Event Monitoring of safety of COVID-19 vaccines in special populations (pregnant and lactating women, children and adolescents, immunocompromised, people with history of allergy, people with prior SARS-CoV-2 infection) (Covid-Vaccine-Monitor CVM)
Cohort monitoring of Adverse Events of Special Interest and COVID-19 diagnoses prior to and after COVID-19 vaccination (ECVM)
CONSIGN study: COVID-19 infection and medicines in pregnancy - a multinational registry based study
Coverage of COVID-19 vaccines in electronic healthcare databases: a protocol template from the ACCESS project
Description of international collaboration in the area of medicines use and effects in COVID-19 affected pregnancies (CONSIGN-International))
Effectiveness of heterologous and booster Covid-19 vaccination in 5 European countries, using a cohort approach in children and adults with a full primary Covid-19 vaccination regimen (Covid Vaccines Effectiveness (CoVE))
Impact of EU label changes and regulatory communication on SARS-CoV-2 adenovirus vector vaccines in context of thrombosis with thrombocytopenia syndrome (TTS): risk awareness and adherence (RiskAwareTTS)
Impact of EU label changes and revised pregnancy prevention programme for medicinal products containing valproate: utilisation and prescribing trends
Impact of EU label changes and revised pregnancy prevention programme for oral retinoid containing medicinal products: utilization and prescribing trends
Implementation of EU risk minimisation measures for medicinal products in clinical guidelines
Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care datasources (CVM Covid19-Vaccine-Monitor-EHR)
Strengthening Use of Real-World Data in Medicines Development: Metadata for Data Discoverability and Study Replicability (MINERVA)